Nutra Pharma Announces Breakthrough Research in the Treatment of Viral Infections
BOCA RATON, Fla.--(BUSINESS WIRE)--Jan 11, 2007 - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that its contract researchers, Eno Research and Development, Inc. (ERDI), recently completed their analysis of a series of microarray studies with ReceptoPharm's antiviral drug candidates in healthy immune cells."The microarray studies indicate that the exposure of healthy immune T-cells to our antiviral drugs activates the primary immune mechanisms," explained Dr. Paul Reid, CEO of ReceptoPharm, Inc. "The expression of one such immune trigger, interferon gamma, is increased by as much as 20 times, acting as an effective antiviral agent, but without the significant negative clinical side effects of other interferon-based therapies. It has certainly helped explain the broad antiviral activity observed with these types of agents. Based upon this data, these products could conceivably be used to substitute for the flu shot in winter or protect against other contagious viral diseases when vaccines are not readily available," he added.
RPI-MN is the lead antiviral drug candidate of Nutra Pharma's holding, ReceptoPharm, Inc. It is being studied for its potential in treating HIV and other viral diseases.
"These findings could in fact revolutionize the antiviral pharmaceutical industry," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Providing patients with a safe, beneficial and cost effective antiviral medicine will allow millions of additional people to obtain treatments that were once out of reach," he concluded.
With the spread of bird flu and worldwide worries about a possible influenza pandemic, antiviral medicines have recently received increased media exposure. During the 2005-2006 flu season, healthcare providers experienced a widespread shortage of the leading antiviral medicine, Tamiflu by Roche (other-otc: RHHBY), which left millions of patients without access to influenza prevention.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The results from the microarray studies should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact
Nutra Pharma Corp.
Investor Relations
David Isserman, 877-895-5647
IR@nutrapharma.com
Clinical Trial Results Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
